New findings underline the role of obesity in T2DM late complications

The results from a large-scale observational study carried out at German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE) and the German Center for Diabetes Research (Deutsches Zentrum fuer Diabetesforschung, DZD), suggest that obesity and weight gain can lead to vascular disorders, the leading cause of disease and death for people with type 2 diabetes. The findings were reported in the paper, ‘BMI and BMI change following incident type 2 diabetes and risk of microvascular and macrovascular complications: the EPIC-Potsdam study’, published in Diabetologia.

Ten-year RCT outcomes demonstrate metabolic surgery more effective than medical therapy in the long-term control of T2DM

The first ever outcomes from ten years of follow-up from a randomised controlled trial assessing metabolic surgery vs. conventional medical therapy, has concluded that surgery is more effective than conventional medical therapy in the long-term control of T2DM. The findings were reported in the paper, ‘Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial’, published in The Lancet.

ReShape Lifesciences to merge with Obalon Therapeutics

ReShape Lifesciences has entered into a definitive merger agreement with Obalon Therapeutics, under which ReShape and Obalon will combine in an all-stock transaction. Under the terms of the merger agreement that has been unanimously approved by the boards of directors of both companies, existing ReShape stockholders will have majority ownership of the combined company immediately following the closing of the merger and Obalon will be renamed ReShape Lifesciences Inc.

Correlation between adolescents with obesity and mental health issues


Half of all adolescents with severe obesity have neuropsychiatric problems, according to a study led by researchers from Lund University and Gothenburg, Sweden. Two thirds of the adolescents suffered from some type of mental health problem, as reported by themselves or their parents. The outcomes were reported in the paper, ‘High prevalence of neurodevelopmental problems in adolescents eligible for bariatric surgery for severe obesity’, published in Acta Paediatrica

Governments' approach to obesity policies destined to fail

Government obesity policies in England over the past three decades have largely failed because of problems with implementation, lack of learning from past successes or failures, and a reliance on trying to persuade individuals to change their behaviour rather than tackling unhealthy environments, claims research by a team at the University of Cambridge funded by the NIHR School for Public Health Research. The findings are reported in the publication, ‘Is obesity policy in England fit for purpose?

Bimagrumab shows promise for weight loss in patients with obesity

Bimagrumab, an antibody that blocks activin type II receptors and stimulates skeletal muscle growth, is safe and effective for treating excess adiposity and metabolic disturbances of adult patients with obesity and type 2 diabetes, according to the findings reported in the paper, 'Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity - A Phase 2 Randomized Clinical Trial', published in JAMA Network.

Could altering mealtimes reduce T2DM risk?

Researchers at the University of Surrey are examining whether altering mealtimes could reduce the risk of developing type 2 diabetes. Led by Dr Denise Robertson, Professor Jonathan Johnston and post graduate researcher, Shantel Lynch, from the University of Surrey, the study will investigate if changing the time we eat during the day could reduce risk factors such as obesity and cholesterol levels that are typically associated with the development of type 2 diabetes.

Study to investigate CA7S metabolite’s role as a novel T2DM therapy

Researchers at Brigham and Women’s Hospital have been awarded a US$3.3M National Institutes of Health Grant to evaluate the CA7S metabolite as a novel therapy for type 2 diabetes; uncover how CA7S production is regulated by the gut microbiome; and determine the contribution of CA7S to type 2 diabetes remission, following bariatric surgery.